Short Term Effects of Synchronized vs. Non-synchronized NIPPV in Preterm Infants.
Launched by UNIVERSITY OF TURIN, ITALY · Sep 18, 2017
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how two different methods of breathing support—synchronized nasal intermittent positive pressure ventilation (SNIPPV) and non-synchronized NIPPV—affect the breathing and heart function of preterm infants (those born before 32 weeks of pregnancy) who are having trouble breathing. This trial is important because it aims to find out which method helps these babies better adapt to breathing on their own, especially when they are first being treated with this non-invasive breathing support right after birth or after being taken off a breathing machine.
To participate in the trial, infants need to be born before 32 weeks of pregnancy and have never received this type of breathing support before, or they should be getting it again after being on a breathing machine. Parents will need to give their consent for their child to join. Unfortunately, babies with certain health issues, like serious brain problems, infections, or major birth defects, cannot take part in this study. If enrolled, families can expect regular monitoring of the baby's heart and breathing responses while using the two different ventilation methods. This trial is currently recruiting participants to help improve care for preterm infants with breathing difficulties.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gestational age at birth \<32 weeks
- • First approach to NIV ventilation (primary or after extubation)
- • Parent's informed consent
- Exclusion Criteria:
- • Neurological (including IVH \> 2° grade) or surgical diseases
- • Sepsis (clinical or laboratory confirmed)
- • Chromosomal or genetic abnormalities
- • Major malformations and congenital anomalies
- • Cardiac problems (including hemodynamically significant PDA)
- • Contraindication to NIV (i.e. nasal trauma and gastrointestinal surgery within the previous 7 days).
About University Of Turin, Italy
The University of Turin, located in Italy, is a prestigious academic institution renowned for its commitment to research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive expertise and resources to advance scientific knowledge and improve patient outcomes. Collaborating with a network of healthcare professionals and researchers, the University of Turin conducts rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its focus on translational research ensures that findings contribute to the development of effective therapies and healthcare solutions, enhancing the overall well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Torino, (To), Italy
Torino, , Italy
Patients applied
Trial Officials
Francesco Cresi, PhD
Study Chair
Città della Salute e della Scienza - Ospedale S.Anna - University of Turin
Alessandra Coscia, Prof.
Study Director
Città della Salute e della Scienza - Ospedale S.Anna - University of Turin
Elena Maggiora, MD
Principal Investigator
Città della Salute e della Scienza - Ospedale S.Anna - University of Turin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials